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diabetic PAI-1 +/+ mice, is weak when compared with
nondiabetic mice (×1.5), and is hardly distinguishable
from the induction observed in PAI-1 −/− mice, at least
for the eye (Fig. 3). Another striking result is that the
level of TGF-beta expression and production by the kid-
ney is higher in PAI-1 −/− mice than in PAI-1 +/+ mice,
in either basal or diabetic conditions. In the absence of
pathologic data, including measurements of the glomeru-
lar basement membrane thickness, it is therefore difficult
to conclude that PAI-1 knockout animals could be pro-
tected towards diabetic nephropathy and that this would
be related to a lower concentration of TGF-beta.
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Reply from the Authors
As we gain further insight into PAI-1–mediated mech-
anisms in disease, it is evident that PAI-1 may indeed
have several functions. Early studies showed that PAI-1
deficiency protects against fibrosis, as in the bleomycin-
induced pulmonary model [1], and this is supported by
our studies in the streptozotocin-induced diabetic mouse
model [2].
However, Hertig and Rondeau demonstrate that in in-
flammatory models of disease, PAI-1 deficiency may pro-
mote pathology. In fact, we have observed development
of cardiac fibrosis in PAI-1−/− mice (unpublished data),
as have Moriwaki et al [3], who also showed significant
macrophage involvement in this process. These observa-
tions strongly suggest that PAI-1 function may be deter-
mined by the inciting process, and modulated by uPA
expression, which may be tissue- or disease-specific.
The comment that induction of TGF-b synthesis is
weak (1.5 ×’s) reflects similar changes in total TGF-b
by Hertig et al (1.9 ×’s) [4]. Active TGF-b was not mea-
sured in our paper. As such, it is provocative to assume
that a seemingly “weak” stimulation of TGF-b protein
by PAI-1 may not have a significant clinical outcome (i.e.,
worsened albuminuria). Our data showed no significant
difference in basal kidney TGF-b expression, which was
significantly reduced in diabetic PAI-1−/− mice (Fig. 3).
Significant structural changes of diabetic nephropathy,
such as glomerular basement membrane thickness and
fractional mesangial volume, are not typically observed
after 4 weeks of diabetes in C57BL6 STZ-induced dia-
betic mice and, in fact, may not appear until ∼6 months
of diabetes. For this reason, these parameters were not
included in our study.
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Does fluvastatin really have an
antioxidant effect in humans?
To the Editor: In the recent issue of Kidney Interna-
tional, Pat et al demonstrated that renal fibrosis after
unilateral ureteral obstruction in rat was attenuated by
the antioxidative effect of fluvastatin [1], a HMG-CoA
reductase inhibitor notable for its additional antioxidant
effect [2]. We undertook this clinical experiment because
no in vivo human data are available addressing the antiox-
idant effect of fluvastatin. The patients studied consisted
of 3 males and 3 females, with an average age of 56.5
years. All had biopsy-proven chronic glomerulonephri-
tis with normal ranges of creatinine clearance and serum
total protein. The mean urinary protein excretion was
